Background/Objectives: Diabetic foot ulcers (DFUs) are a common and serious complication of diabetes, often leading to infection, amputation, and reduced quality of life. Platelet-rich plasma (PRP) therapy has emerged as a promising treatment due to its potential to accelerate wound healing through growth factors and cytokines. Despite growing interest, evidence on PRP’s efficacy and safety in DFU management remains variable. This article critically reviews recent studies to evaluate the effectiveness of PRP in promoting ulcer healing, while examining methodological rigor, ethical considerations, and research parameters to provide a comprehensive, evidence-based assessment for clinical application. Materials and Methods: This review explores the biological mechanisms underlying platelet-rich plasma (PRP) as an adjunctive therapy for DFUs, focusing on its regenerative capabilities. PRP is an autologous concentration of platelets containing growth factors and bioactive molecules that promote angiogenesis, cellular proliferation, and extracellular matrix remodeling. Various application methods—topical, injectable, gel-based, and PRP-enhanced dressings—are examined. The review also evaluates the efficacy of PRP as monotherapy and in combination with other interventions such as debridement and split-thickness skin grafting. Results: Clinical studies suggest that PRP, particularly when used alongside surgical debridement or skin grafting, significantly enhances healing outcomes in patients with non-healing DFUs. It provides a biologically favorable environment for tissue regeneration while reducing inflammation and potentially exhibiting antimicrobial properties. However, variability in PRP preparation techniques, application protocols, and patient selection criteria presents challenges to standardization and broader clinical adoption. Conclusions: While PRP therapy demonstrates significant potential in the management of diabetic foot ulcers, further randomized controlled trials with standardized methodologies are essential to establish optimal treatment protocols and confirm long-term benefits. PRP offers a minimally invasive, autologous, and biologically active treatment modality that may serve as a vital component in the multidisciplinary approach to DFU management.

Chronic wounds represent a significant global healthcare challenge, affecting millions of patients and imposing substantial economic burdens on healthcare systems. Traditional wound management approaches often fail to address the complex pathophysiology underlying chronic wounds, including persistent inflammation, impaired angiogenesis, and disrupted extracellular matrix remodeling. Three-dimensional (3D) bioprinting has emerged as a transformative technology that enables the fabrication of patient-specific, biomimetic tissue constructs capable of addressing these intricate challenges. This comprehensive review synthesizes recent advances in 3D bioprinting for chronic wound treatment, examining bioprinting technologies, biomaterial innovations, mechanisms of wound healing, and clinical applications. Recent studies demonstrate that bioprinted constructs incorporating living cells, growth factors, and bioactive molecules can significantly accelerate wound closure, enhance vascularization, and restore functional skin architecture. Notable innovations include in situ bioprinting systems, photosynthetic scaffolds for oxygen delivery, and immunomodulatory bioinks. While significant technical challenges remain—including vascularization, scalability, and regulatory approval—the integration of advanced bioprinting techniques with regenerative medicine principles offers unprecedented opportunities for personalized chronic wound care and improved patient outcomes.

Chronic wounds represent a significant global healthcare challenge, affecting millions of patients and imposing substantial economic burdens on healthcare systems. Traditional wound management approaches often fail to address the complex pathophysiology underlying chronic wounds, including persistent inflammation, impaired angiogenesis, and disrupted extracellular matrix remodeling. Three-dimensional (3D) bioprinting has emerged as a transformative technology that enables the fabrication of patient-specific, biomimetic tissue constructs capable of addressing these intricate challenges. This comprehensive review synthesizes recent advances in 3D bioprinting for chronic wound treatment, examining bioprinting technologies, biomaterial innovations, mechanisms of wound healing, and clinical applications. Recent studies demonstrate that bioprinted constructs incorporating living cells, growth factors, and bioactive molecules can significantly accelerate wound closure, enhance vascularization, and restore functional skin architecture. Notable innovations include in situ bioprinting systems, photosynthetic scaffolds for oxygen delivery, and immunomodulatory bioinks. While significant technical challenges remain—including vascularization, scalability, and regulatory approval—the integration of advanced bioprinting techniques with regenerative medicine principles offers unprecedented opportunities for personalized chronic wound care and improved patient outcomes.

Background: Early and accurate assessment of traumatic injuries in pediatric patients is critical for timely diagnosis and prevention of missed associated injuries. The Pediatric Trauma Support System (PTSS) is a digital clinical decision support tool designed to integrate physiological parameters, trauma mechanism, and demographic characteristics to provide automated trauma risk assessment in children. Aim: To evaluate the clinical applicability of the Pediatric Trauma Support System (PTSS) in the primary assessment of pediatric patients with blunt trauma and to analyze the sensitivity of the Pediatric Trauma Score (PTS), particularly in children under one year of age. Materials and Methods: A prospective observational study was conducted in the Emergency Department and the Department of Pediatric Surgery at the University Hospital “St. George”, Plovdiv, Bulgaria. The study included 100 pediatric patients aged 0-18 years presenting with blunt traumatic injuries. Standard clinical evaluation was performed for all patients, including assessment of vital signs and neurological status using the Glasgow Coma Scale (GCS). PTSS was used to automatically calculate the Pediatric Trauma Score (PTS) and generate recommendations for imaging diagnostics. Twenty-five patients were under two years of age, including nine infants younger than one year (6 boys and 3 girls). Demographic and clinical variables were analyzed descriptively. Results: Among the nine patients under one year of age, all had PTS values below the normal age-adjusted threshold. In cases of mild trauma the PTS was 9/12, while in moderate trauma it was 8/12. The PTSS algorithm generated recommendations for head computed tomography (CT) and abdominal ultrasound in all infants. Head imaging was performed in all nine patients, revealing a parietal bone fracture in one 27-day-old infant. Abdominal ultrasound was not performed in clinical practice despite the algorithmic recommendation. In patients older than one year with similar trauma severity, PTS values were higher (11/12), and PTSS recommended only head CT without additional abdominal imaging. Conclusion: PTSS provides a structured and automated approach to pediatric trauma assessment by integrating PTS with clinical and demographic parameters. The system demonstrates increased sensitivity in infants under one year of age, where physiological characteristics may mask significant associated injuries. Automated recommendations for additional imaging may contribute to earlier detection of occult injuries and improved patient safety in pediatric trauma care.